RxDoctor Payments Data

Andrew Scatola, MD

Advanced Heart Failure and Transplant Cardiology · Hartford, CTNPI 1003173493

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $28,855 of the $35,784 with a category attached, or 80.6%. Boehringer Ingelheim accounts for 80.9% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2022 at $18,107 and has fallen 97.6% since, to $431 in 2025.

$35,784in general payments, 2019–2025

Across 145 payments — averaging $246.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$29K
  • Lilly USA, LLC$3K
  • Abbott$871
  • Medtronic$839
  • AstraZeneca$534
  • Pfizer$276
  • plus $1K from 12 others
$9,500in research payments, 2019–2025

Across 1 payment — averaging $9500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$10K

What the payments were for

  • Speaking & faculty fees$28,85581%
  • Travel & lodging$2,3837%
  • Food & beverage$4,51213%
  • Education$340%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Connecticutto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$58,595
Medicare patients
93
Services billed
414

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis25$1,105,294
JardianceEmpagliflozin61$94,242
EntrestoSacubitril/Valsartan44$69,646
FarxigaDapagliflozin Propanediol26$29,220
EliquisApixaban22$19,962
Torsemide86$2,172
Eplerenone19$1,830
Midodrine Hcl17$1,340
Spironolactone88$971
Metoprolol Succinate57$793
Potassium Chloride14$238
Furosemide36$229
Carvedilol13$186
Atorvastatin Calcium12$88
Losartan Potassium15$31

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$276$1,125,25647 claims
Boehringer IngelheimJardiance$28,932$94,24261 claims
NovartisEntresto$143$69,64644 claims
AstraZenecaFarxiga$534$29,22026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Connecticuton file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →